Cargando…

Topical Application of the PI3Kβ-Selective Small Molecule Inhibitor TGX-221 Is an Effective Treatment Option for Experimental Epidermolysis Bullosa Acquisita

Class I phosphoinositide 3-kinases (PI3K) have been implemented in pathogenesis of experimental epidermolysis bullosa acquisita (EBA), an autoimmune skin disease caused by type VII collagen (COL7) autoantibodies. Mechanistically, inhibition of specific PI3K isoforms, namely PI3Kβ or PI3Kδ, impaired...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zillikens, Hannah, Kasprick, Anika, Osterloh, Colin, Gross, Natalie, Radziewitz, Michael, Hass, Cindy, Hartmann, Veronika, Behnen-Härer, Martina, Ernst, Nancy, Boch, Katharina, Vidarsson, Gestur, Visser, Remco, Laskay, Tamás, Yu, Xinhua, Petersen, Frank, Ludwig, Ralf J., Bieber, Katja
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8452940/ https://www.ncbi.nlm.nih.gov/pubmed/34557502 http://dx.doi.org/10.3389/fmed.2021.713312

Ejemplares similares

Whole-Genome Expression Profiling in Skin Reveals SYK As a Key Regulator of Inflammation in Experimental Epidermolysis Bullosa Acquisita
por: Samavedam, Unni K., et al.
Publicado: (2018)

T cells mediate autoantibody-induced cutaneous inflammation and blistering in epidermolysis bullosa acquisita
por: Bieber, Katja, et al.
Publicado: (2016)

Therapeutic Effect of a Novel Phosphatidylinositol-3-Kinase δ Inhibitor in Experimental Epidermolysis Bullosa Acquisita
por: Koga, Hiroshi, et al.
Publicado: (2018)

Epidermolysis Bullosa Acquisita: The 2019 Update
por: Koga, Hiroshi, et al.
Publicado: (2019)

Epidermolysis bullosa acquisita()
por: Miyamoto, Denise, et al.
Publicado: (2022)

Treatment with anti‐neonatal Fc receptor (FcRn) antibody ameliorates experimental epidermolysis bullosa acquisita in mice
por: Kasprick, Anika, et al.
Publicado: (2020)

Pathological Relevance of Anti-Hsp70 IgG Autoantibodies in Epidermolysis Bullosa Acquisita
por: Tukaj, Stefan, et al.
Publicado: (2022)

Epidermolysis bullosa acquisita: current diagnosis and therapy
por: Mehren, Christine R., et al.
Publicado: (2011)

Epidermolysis Bullosa Acquisita: A Case Report
por: Kumetz, Erik A., et al.
Publicado: (2020)

Epidermolysis Bullosa Acquisita—Current and Emerging Treatments
por: Tešanović Perković, Deša, et al.
Publicado: (2023)

Epidermolysis bullosa acquisita: an uncommon cause of esophageal stricture
por: Figueredo, Carlos, et al.
Publicado: (2021)

Epidermolysis Bullosa Acquisita: A Report of Four Cases
por: De, Abhishek, et al.
Publicado: (2022)

Preventive but Not Therapeutic Topical Application of Local Anesthetics Can Inhibit Experimental Epidermolysis Bullosa Acquisita in Mice
por: Wen, Lifang, et al.
Publicado: (2021)

Meta-analysis of the clinical and immunopathological characteristics and treatment outcomes in epidermolysis bullosa acquisita patients
por: Iwata, Hiroaki, et al.
Publicado: (2018)

Clinical Presentation, Pathogenesis, Diagnosis, and Treatment of Epidermolysis Bullosa Acquisita
por: Ludwig, Ralf J.
Publicado: (2013)

Acute renal failure in a patient with epidermolysis bullosa acquisita
por: Zhao, Guowei, et al.
Publicado: (2017)

Epidermolysis bullosa acquisita treated with ustekinumab: A case report
por: Prosty, Connor, et al.
Publicado: (2022)

Fcγ Receptor IIB Controls Skin Inflammation in an Active Model of Epidermolysis Bullosa Acquisita
por: Kovacs, Balint, et al.
Publicado: (2020)

EPIDERMOLYSIS BULLOSA ACQUISITA WITH MODERATELY SEVERE DYSPHAGIA DUE TO ESOPHAGEAL STRICTURES
por: Tu, Jenny, et al.
Publicado: (2011)

An atypical case of pediatric epidermolysis bullosa acquisita: Review of diagnosis and pitfalls
por: Patel, Ashaki, et al.
Publicado: (2021)

The development of mucous membrane epidermolysis bullosa acquisita in a pediatric patient
por: Rentfro, Kathryn, et al.
Publicado: (2021)

Risk factors and sequelae of epidermolysis bullosa acquisita: A propensity-matched global study in 1,344 patients
por: Kridin, Khalaf, et al.
Publicado: (2023)

Metabolite analysis distinguishes between mice with epidermolysis bullosa acquisita and healthy mice
por: Schönig, Sarah, et al.
Publicado: (2013)

Case Report: Diagnostic and Therapeutic Challenges in Severe Mechanobullous Epidermolysis Bullosa Acquisita
por: Schauer, Franziska, et al.
Publicado: (2022)

Diagnosis of Epidermolysis Bullosa Acquisita: Multicentre Comparison of Different Assays for Serum Anti-type VII Collagen Reactivity
por: HOLTSCHE, Maike Marleen, et al.
Publicado: (2021)

C-type lectin receptor expression is a hallmark of neutrophils infiltrating the skin in epidermolysis bullosa acquisita
por: Guerrero-Juarez, Christian F., et al.
Publicado: (2023)

Childhood Epidermolysis Bullosa Acquisita: Confirmation of Diagnosis by Skin Deficient in Type VII Collagen, Enzyme-linked Immunosorbent Assay, and Immunoblotting
por: Goyal, Nupur, et al.
Publicado: (2016)

Porphyria Cutanea Tarda Masquerading as Epidermolysis Bullosa Acquisita: A Report of Two Cases
por: Deen, Kristyn, et al.
Publicado: (2015)

Cytoskeletal Regulation of Inflammation and Its Impact on Skin Blistering Disease Epidermolysis Bullosa Acquisita
por: Kopecki, Zlatko, et al.
Publicado: (2016)

Epidermolysis bullosa acquisita as an adverse effect from rituximab therapy: A case report
por: Wu, Xueqiong, et al.
Publicado: (2020)

Luteolin peracetate and gossypolone inhibit immune complex-mediated neutrophil activation in vitro and dermal-epidermal separation in an ex vivo model of epidermolysis bullosa acquisita
por: Yang, Kai, et al.
Publicado: (2023)

Mycophenolate mofetil (MMF) in the treatment of epidermolysis bullosa acquisita (EBA) long-term follow-up
por: Sami, Naveed
Publicado: (2015)

The Syk Tyrosine Kinase Is Required for Skin Inflammation in an In Vivo Mouse Model of Epidermolysis Bullosa Acquisita
por: Németh, Tamás, et al.
Publicado: (2017)

Refractory Epidermolysis Bullosa Acquisita with Chronic Graft-versus-Host Disease Successfully Treated with Rituximab
por: Han, Ju Hee, et al.
Publicado: (2023)

Case Report: Biological treatment of epidermolysis bullosa acquisita: report on four cases and literature review
por: Szymański, Konrad, et al.
Publicado: (2023)

Therapeutic effects of Fc gamma RIV inhibition are mediated by selectively blocking immune complex-induced neutrophil activation in epidermolysis bullosa acquisita
por: Haeger, Swantje C., et al.
Publicado: (2022)

The complement receptor C5aR2 regulates neutrophil activation and function contributing to neutrophil-driven epidermolysis bullosa acquisita
por: Seiler, Daniel L., et al.
Publicado: (2023)

Accessible Diagnostic Methods to Differentiate between Epidermolysis Bullosa Acquisita and Other Subepidermal Autoimmune Bullous Diseases
por: Kridin, Khalaf
Publicado: (2018)

Epidermolysis Bullosa Acquisita: A Case Report of a Rare Clinical Phenotype and a Review of Literature
por: Beiu, Cristina, et al.
Publicado: (2019)

Vesiculobullous Erythema Elevatum Diutinum: a Rare Variant With Epidermolysis Bullosa Acquisita-like Immunofluorescence Findings
por: Yalici-Armagan, Basak, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_87fs8e32omfnd0mko4qro092o1